WuXi PharmaTech Inks New Pact To Synthesize Compounds For AstraZeneca
This article was originally published in PharmAsia News
Executive Summary
BEIJING - Shanghai-headquartered WuXi PharmaTech, one of China's leading contract research organizations, this week signed a new agreement to synthesize compounds according to AstraZeneca's designs